Abstract

Aim

Atherosclerosis (AS) is one of the main causes of cardiovascular disease which might lead to myocardial infarction or stroke and further leads to fatality.

Method

In this study, we have designed an anti-inflammatory cytokine interleukin-10 (IL10) delivery system to effectively alleviate the inflammation of atherosclerosis plaque. The targeted delivery of IL10 to the atherosclerotic plaques was achieved by cRGD conjugated liposomes (IL10-cRGD-Lip).

Results

The IL10-cRGD-Lip of size 179.4 ± 10.91 nm having PDI 0.14 ± 0.04 with a surface charge of +18.34 ± 1.36 mV was prepared. The in-vitro analysis clearly suggests that IL10-cRGD-Lip sustains the release of IL10 and could significantly reduce ROS and NO. The immuno-staining results revealed that IL-1β and TNF-α were down-regulated after the treatment with IL10-cRGD-Lip in Lipopolysaccharide (LPS) stimulated RAW 264.7 cells.

Conclusion

the in-vitro results clearly suggest that anti-inflammatory cytokine IL10 could be used for the cure of inflammatory maladies including atherosclerosis.

中文翻译：

---

抗炎细胞因子 IL10 负载 cRGD 脂质体用于靶向治疗动脉粥样硬化

摘要

目标

动脉粥样硬化（AS）是心血管疾病的主要原因之一，可能导致心肌梗塞或中风，并进一步导致死亡。

方法

在这项研究中，我们设计了一种抗炎细胞因子白细胞介素 10 (IL10) 递送系统，以有效缓解动脉粥样硬化斑块的炎症。通过 cRGD 偶联脂质体 (IL10-cRGD-Lip) 将 IL10 靶向递送至动脉粥样硬化斑块。

结果

制备尺寸为 179.4 ± 10.91 nm 的 IL10-cRGD-Lip，PDI 为 0.14 ± 0.04，表面电荷为 +18.34 ± 1.36 mV。体外分析清楚地表明，IL10-cRGD-Lip 可维持 IL10的释放，并可显着降低 ROS 和 NO。免疫染色结果显示，在脂多糖 (LPS) 刺激的 RAW 264.7 细胞中用 IL10-cRGD-Lip 处理后，IL-1β 和 TNF-α 下调。

结论

体外结果清楚地表明抗炎细胞因子IL10可用于治疗包括动脉粥样硬化在内的炎症性疾病。